{"id":"W2562336370","doi":"10.1182/blood.v118.21.443.443","title":"Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma: A Phase 2 Study Update","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Brentuximab vedotin; Medicine; Anaplastic large-cell lymphoma; Internal medicine; Oncology; CD30; Refractory (planetary science); Phases of clinical research; Adverse effect; Lymphoma; Clinical trial; Surgery; Gastroenterology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001377981,0.0005396355,0.001124551,0.0002449301,0.0001410978,0.0006467664,0.0003379653,0.0004788349,0.001527977],"category_scores_gemma":[0.0005466426,0.000238011,0.0006954488,0.0003068045,0.0002568653,0.0004155698,0.0001803194,0.0009791628,0.0003366603],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003719763,"about_ca_system_score_gemma":0.0006983898,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005723586,"about_ca_topic_score_gemma":0.001753184,"domain_scores_codex":[0.999765,0.0001120537,0.00001952424,0.00003039529,0.0000379494,0.00003517952],"domain_scores_gemma":[0.9997174,0.00006949197,0.00005898461,0.00001930779,0.00003158797,0.0001031691],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.2548649,0.03777483,0.05081181,0.004058455,0.005023722,0.001156872,0.0008347692,0.003860605,0.0763577,0.0004636584,0.01352712,0.5512657],"study_design_scores_gemma":[0.4748577,0.3811595,0.102689,0.0004086424,0.002909745,0.002433968,0.0002020798,0.003775077,0.007353673,0.0003411184,0.02378761,0.0000818674],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9787613,0.01579498,0.0005306049,0.0004321914,0.00008987588,0.001304377,0.0009159034,0.0000835719,0.002087195],"genre_scores_gemma":[0.9819927,0.009982637,0.001722985,0.001283775,0.000134122,0.0009549229,0.002865676,0.00002197462,0.001041102],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001527977,"threshold_uncertainty_score":0.007287562,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01237204693855759,"score_gpt":0.2338100124608789,"score_spread":0.2214379655223213,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}